Why a registered Wegovy pen may still not reach the SUS pharmacy, and how Conitec's technical process decides what the public system can offer.

Why Anvisa registration doesn't mean Wegovy SUS access

If Wegovy is already registered with Anvisa, why can't you pick it up at your local SUS pharmacy? That's the most common question people ask about Wegovy SUS, and it's a fair one. Most of the confusion comes from treating three separate steps as one: registration, incorporation, and dispensing to patients.

Registration means Anvisa reviewed safety, quality, and efficacy data and allowed the product to be sold in Brazil. It doesn't decide whether the public system pays for it. That job belongs to incorporation, handled by a separate technical process at Conitec. Dispensing comes last, once everything else is settled.

Don't take our word for the details. Check the approval date and the indication in the current Wegovy bula on Anvisa's Bulário Eletrônico, and look up the status of any incorporation request on the Conitec portal. The topic is still moving, so this post doesn't promise a date or an outcome. If you want to follow updates without getting lost in rumors, OzemBlog breaks these steps down in plain language.

How Conitec's process works, step by step

Medicine box and injection pens for medical use

Conitec, the National Commission for Incorporation of Technologies in the SUS, carries out the technical assessment and issues a recommendation. The final call belongs to the Ministry of Health. Two federal rules set the framework: Lei 12.401/2011 and Decreto 7.646/2011.

The sequence usually runs like this. Someone files an incorporation request. A technical report reviews the evidence, the cost, and the comparators. That report goes to public consultation, where anyone can send contributions. The committee then meets, weighs the evidence and the feedback, and issues its recommendation.

A favorable recommendation still isn't the finish line. The Ministry has to publish a portaria in the Diário Oficial da União before incorporation takes effect. There's no guaranteed deadline. Meetings get postponed, requests go back for more data, and new consultations open. Treat any date you see as a provisional estimate.

What weighs in the evaluation: efficacy, cost, and comparators

Efficacy

The evidence file leans on large clinical trials. The STEP 1 trial, published in the New England Journal of Medicine in 2021, tested once-weekly semaglutide in adults with overweight or obesity and measured how much weight participants lost. SELECT asked a different question. Published in the same journal in 2023, it tested whether semaglutide reduces major cardiovascular events in people with overweight or obesity and established heart disease, without diabetes. In short, STEP measures weight change, while SELECT measures heart outcomes over time. The committee reads both alongside the safety data.

Cost-effectiveness

Conitec uses an incremental cost-effectiveness ratio, or ICER. In plain terms, it divides the extra money the system would spend by the extra health a patient gains. The threshold used to judge that ratio is described in Conitec's methodology. If the ratio sits above that line, the price usually needs to come down before the request looks favorable. Drug prices in Brazil are also regulated by CMED, which sets maximum sale prices.

Comparator

The comparator can flip the result. Measured against no treatment, a drug can look like a big gain. Measured against an option the SUS already uses, the gain may shrink, and the cost difference becomes the main story. The protocols in force list the obesity options the system already offers, so read the comparator section of the technical report closely. It tells you what the committee chose as the baseline.

Budget impact

Budget impact asks how many people would be treated and what the yearly bill would be for the system. The answer rests on assumptions about the eligible population, how many patients would start treatment, and the price. Change any of those inputs and the total moves. That's why the report includes scenarios. Read them as what-if exercises, not forecasts.

Who could be eligible: indication, BMI, and protocol

Wegovy and Ozempic share the same active ingredient, semaglutide, but they're approved for different purposes. Ozempic is indicated for type 2 diabetes. Wegovy is indicated for long-term weight management. The indication shapes who a request targets, so a request for one doesn't automatically cover the other. Read the exact wording in the bula, not a summary.

Clinical criteria, including BMI and related conditions, usually appear in protocols and therapeutic guidelines, such as the Ministry of Health's obesity PCDT. These documents define who the public system treats, and they get updated. Check the current version and its publication date on the Ministry's website. The indication on your prescription also matters, because it shapes what a public program can release.

Don't assume you qualify because a friend does. Eligibility depends on your clinical picture, and your doctor is the right person to check it against the protocol in force.

How to read official documents without falling for loose news

Official documents are less exciting than headlines, but they're far more reliable. Use this reading routine:

Check the Conitec agenda and the minutes (atas) published after each meeting.
Read the public consultation documents and the contributions received.
Watch the Diário Oficial da União for the final portaria.

A favorable recommendation is not the same as a concluded incorporation. It tells you the committee found the evidence sufficient, but it doesn't guarantee a pharmacy shelf next week. Even after a portaria, availability depends on central purchasing, agreements among federal, state, and municipal governments, and local stock. Each step takes time.

Be skeptical of any article that says a medicine is "already free" without citing the portaria's number and publication date. Solid reporting gives you a document you can open and verify. For a structured way to read these records and follow the process over time, try the OzemBlog's reading guide on this topic.

What to do in the meantime: continuity and your doctor

Don't stop your current treatment while you wait for free access, and don't switch medicines on your own. Decisions about changing or stopping a treatment belong with your doctor, who can plan any transition safely. If cost is the barrier, say so. Your doctor can explain alternatives and what the medicine would cost outside the system. OzemBlog's articles on continuity of care can help you frame that conversation.

Bring specific questions to your next appointment. Does my indication fit my case? Is there an alternative available through the SUS? What would this treatment cost if I paid privately? Write the answers down so you can compare any future decision with your real situation.

Medicines may support weight loss when combined with changes in eating and regular physical activity. They're a tool, not a cure, and results vary from person to person. Side effects and monitoring also need medical follow-up. Writing your questions before a visit makes the conversation more useful.

The best next step is a conversation with your healthcare team. Bring your questions, your records, and your concerns. They know your history and can tell you what fits your case today, even while the national discussion continues.

FAQ

Is Wegovy already free in SUS pharmacies?

This post can't confirm that. Check the Conitec portal and the Diário Oficial da União for the latest status, because a recommendation or a portaria can change the picture.

Does Anvisa registration mean the SUS has to pay for a medicine?

No. Registration confirms that a product can be sold in Brazil. Incorporation into the SUS is a separate evaluation by Conitec, followed by a decision from the Ministry of Health.

What does a Conitec recommendation mean?

It is the commission's technical opinion after reviewing evidence, cost, and public contributions. It isn't final until the Ministry publishes a portaria in the Diário Oficial da União.

Can I switch to a cheaper medicine on my own while I wait?

It's not a good idea. Changing medicines without medical guidance can affect both your treatment and your safety. Ask your doctor about alternatives instead.

Sources

Why Anvisa registration doesn't mean Wegovy SUS access

How Conitec's process works, step by step

Medicine box and injection pens for medical use